Sugi Predict

Sugi Predict / Targets / SOS1

SOS1

Son of sevenless homolog 1 · Q07889 · SOS1 on Sugi Atlas →

100,246 patent compounds predicted against SOS1, 60,274 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL405989 SCHEMBL405989 0.44 15/20
SCHEMBL406898 SCHEMBL406898 0.41 15/20
SCHEMBL406287 SCHEMBL406287 0.46 14/20
SCHEMBL404682 SCHEMBL404682 0.43 14/20
SCHEMBL405070 SCHEMBL405070 0.45 12/20
SCHEMBL406083 SCHEMBL406083 0.42 12/20
SCHEMBL462902 SCHEMBL462902 0.46 11/20
SCHEMBL462918 SCHEMBL462918 0.46 11/20
SCHEMBL406225 SCHEMBL406225 0.43 11/20
SCHEMBL438079 SCHEMBL438079 0.39 10/20
SCHEMBL462813 SCHEMBL462813 0.39 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL439453) 0.39 10/20
SCHEMBL404796 SCHEMBL404796 0.42 9/20
SCHEMBL698053 SCHEMBL698053 0.37 9/20
SCHEMBL405985 SCHEMBL405985 0.40 8/20
SCHEMBL405004 SCHEMBL405004 0.35 8/20
SCHEMBL195272 SCHEMBL195272 0.57 7/20
SCHEMBL195273 SCHEMBL195273 0.57 7/20
SCHEMBL194667 SCHEMBL194667 0.54 7/20
SCHEMBL128685 SCHEMBL128685 0.55 6/20

Clinical trials — most relevant to SOS1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Proteome-based Immunotherapy of Lung Cancer Brain Metastases PHASE2/PHASE3UNKNOWN
Proteome-based Personalized Immunotherapy of Glioblastoma PHASE2/PHASE3UNKNOWN
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome PHASE2WITHDRAWN
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer PHASE1/PHASE2COMPLETED
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 PHASE2COMPLETED
SCARFREE-001: Verteporfin for Scar Prevention PHASE2NOT_YET_RECRUITING
KRAS Wild-type Metastatic Colorectal Cancer Trial PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma PHASE1COMPLETED
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
is the Sclerostin Marker of Chronic Periodontitis nanCOMPLETED
Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients nanUNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors nanNO_LONGER_AVAILABLE
Eosinophil Induced Remodelling in Asthma nanCOMPLETED
Natural History and Genetic Studies of Usher Syndrome nanCOMPLETED
Study of Metabolic Modifications in Children With Noonan Syndrome nanCOMPLETED
RASopathy Biorepository nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SOS1 binder may also engage these)

ProteinNameSimilarity
Q62245 — 1.000 Q62245 →
Q02384 — 0.999 Q02384 →
SOS2 Son of sevenless homolog 2 0.997 landscape →
RAPGEF4 Rap guanine nucleotide exchange factor 4 0.980 landscape →
Q9H8V3 — 0.975 Q9H8V3 →
VAV1 Proto-oncogene vav 0.975 landscape →
Q9R0C8 — 0.974 Q9R0C8 →
Q07139 — 0.974 Q07139 →
Q9Z1C7 — 0.974 Q9Z1C7 →
Q8AVG0 — 0.972 Q8AVG0 →
Q8K3G9 — 0.972 Q8K3G9 →
P54100 — 0.972 P54100 →
Q9UKW4 — 0.971 Q9UKW4 →
Q9H3E2 — 0.971 Q9H3E2 →
P29994 — 0.971 P29994 →
Q9EQZ6 — 0.970 Q9EQZ6 →
P97878 — 0.969 P97878 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.969 landscape →
Q8BPM2 — 0.969 Q8BPM2 →
Q08DN7 — 0.969 Q08DN7 →
Q9TU34 — 0.969 Q9TU34 →
A7MBL8 — 0.969 A7MBL8 →
A2AT37 — 0.969 A2AT37 →
A6NI28 — 0.969 A6NI28 →
Q9HAU5 — 0.969 Q9HAU5 →
Q08CZ0 — 0.968 Q08CZ0 →
A2APV2 — 0.968 A2APV2 →
Q5RID7 — 0.968 Q5RID7 →
Q56A27 — 0.968 Q56A27 →
Q9TTY2 — 0.968 Q9TTY2 →